Guideline: American Heart Association examines the challenges of cardiovascular disease and breast cancer
Current breast cancer treatments can negatively affect cardiovascular health. Recently, the American Heart Association released its first scientific statement on cardiovascular disease and breast cancer. This statement includes a comprehensive overview of the prevalence of both diseases, shared risk factors, cardiotoxic effects of therapy and the prevention and treatment of cardiovascular disease in breast cancer patients. (5/2/18)
Contents
At a glance | Questions for your doctor |
Findings | In-depth |
Clinical trials | Limitations |
Guidelines | Resources |
STUDY AT A GLANCE
This American Heart Association statement is about:
cardiovascular disease and breast cancer.
Why is this statement important?
Women with breast cancer are often treated with therapies that impact their risk of cardiovascular disease (CVD). CVD and breast cancer have several overlapping risk factors; many of these can be modified to reduce risk. The American Heart Association reviewed the prevention and treatment of cardiovascular disease in the context of breast cancer treatment.
Findings:
Cardiovascular disease and breast cancer are significant causes of disease and death in the United States.
- CVD is the primary cause of death in women. Annually 1 in 3.3 women die of CVD and 1 in 31.5 die of breast cancer.
- In postmenopausal women, CVD is higher among breast cancer survivors than women without breast cancer. This is partially due to heart damage from cancer treatment.
Cardiovascular disease and breast cancer share common risk factors, including:
- diet
- alcohol
- physical activity
- sedentary lifestyle
- weight
- age
- postmenopausal hormone replacement therapy ()
Some breast cancer treatments can lead to early or delayed heart damage. Although relatively rare, severe CVD can lead to heart failure and death. Treatment-related cardiac damage, however, is not rare. The cardiac effects of the most common breast cancer therapies are described below.
- Anthracyclines (e.g., doxorubicin and epirubicin): These are agents which are commonly used in breast cancer treatment, cause heart damage at all doses; the risk of heart damage increases with higher doses.
- Endocrine therapy (e.g., tamoxifen and aromatase inhibitors): These agents decrease cancer recurrence and improve survival in patients with , hormone receptor-positive breast cancer. Tamoxifen is associated with increased risk of blood clots. Aromatase inhibitors are known to raise a patient’s cholesterol level up to 2.3 times.
- therapies (e.g., Herceptin and Perjeta): These two FDA-approved antibodies are used to inhibit tumors. They are associated with heart dysfunction; however, their effects are not significant and are mostly reversible.
- Radiation therapy: Radiation to the chest has a significant risk of CVD that increases mortality and limits use of radiation therapy for cancer treatment. With modern radiation therapy techniques such side effects are less common.
Given the association of cardiotoxicity with many cancer treatments, monitoring the heart function before, during and after cancer treatment is important. Yet no definitive guidelines exist for prevention of cardiotoxicity in breast cancer patients. Coordination of cardiology and oncology providers is necessary to determine appropriate treatment, particularly for patients with a history of CVD or who are at high risk of CVD during treatment.
Reducing the cardiotoxic impact of cancer therapy may include:
- Delivering doxorubicin slowly via infusion or using liposomes (e.g.,doxil)
- Infusing the medication slowly over at 6 or more hours, or administering it via liposomes reduce cardiovascular and harmful effects.
- Treatment with cardiovascular medications during breast cancer treatment
- Several CV medications have been tested in combination with breast cancer treatments with promising results. In some patients, treatment with beta blockers (e.g., carvedilol) and/or (e.g., lisinopril) with breast cancer therapy can reduce the risk of heart events.
- Treatment with the medication Dexrazoxane during breast cancer treatment
- Dexrazoxane is a drug that reduces cell damage. Trials show that dexrazoxane with the anthracyclines doxorubicin or epirubicin reduces heart events by 65-82% with no impact on progression-free survival, overall survival or response rates.
- A consistent level of exercise
- In a trial of 2,973 women with non-metastatic breast cancer, researchers found that increasing exercise appeared to reduce cardiotoxicity events. Women who exercised more than 9-10 hours per week had 23% fewer CV events, 26% lower risk of coronary artery disease and 29% lower risk of heart failure.
- Survivorship programs
- Having a definite plan to manage cardiotoxicity during survivorship can improve long-term outcomes.
Survivorship care plans
Breast cancer survivors at higher risk for CVD include patients who have:
- a prior history of CVD
- receive more than 240 mg/m2 of doxorubicin
- received radiation of over 30 gray
- received radiation plus doxorubicin (or another anthracycline) or receive a high-dose cyclophosphamide
Having a definite plan to manage cardiotoxicity during survivorship can improve long-term outcomes. Survivorship care plans may include:
- Monitoring and treating general CV risks (e.g., high blood pressure, diabetes mellitus, and high cholesterol and lifestyle risks).
- Weight management strategies.
- Maintaining physical activity.
- Post-treatment cardiac imaging (as needed).
- An appropriate surveillance regimen, depending on cancer treatment agents and doses received.
What does this mean for me?
If you are a current breast cancer patient or a breast cancer survivor, your risk of cardiovascular disease may be elevated due to cancer treatment. It is important to know that CVD and breast cancer have several overlapping risk factors. Many of these risk factors, such as diet and physical activity, can be modified to reduce risk. It is important to disclose any prior heart conditions to your health care provider. You and your health care provider may want to discuss whether there are modifications to cancer therapy or monitoring of heart function that are warranted.
Share your thoughts on this XRAYS article by taking our brief survey
Posted 5/2/18
Reference
Mehta, L. et al., Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association, Circulation. Feb. 1, 2018;137(8): e30-e66.
Disclosure
FORCE receives funding from industry sponsors, including companies that manufacture cancer drugs, tests and devices. All XRAYS articles are written independently of any sponsor and are reviewed by members of our Scientific Advisory Board prior to publication to assure scientific integrity.
National Comprehensive Cancer Network (NCCN) Survivorship Guidelines include specific recommendations related to cardiovascular disease (CVD) in cancer survivors:
- Doctors should evaluate patients for heart failure risk factors and treat patients as indicated:
- hypertension
- dyslipidemia (high cholesterol)
- diabetes mellitus
- family history of cardiomyopathy
- older than age 65
- low normal cardiac output
- smoking
- obesity
- review medications, alcohol use and other substance use
- review treatment history, including chemotherapy, , androgen or deprivation therapy or radiation therapy to the chest wall
- Survivors should be evaluated for signs and symptoms of heart failure through history and physical exam, including the following:
- Asked if they have shortness of breath or chest pain after physical activities or exercise.
- Asked if they have shortness of breath when lying flat, if they wake up at night needing to get air or have persistent leg swelling.
- Physical exam should look for signs of cardiac volume overload.
- Doctors should discuss the benefits and risks of aspirin to help protect against heart disease.
- People showing evidence of heart disease should have a complete cardiac workup, including imaging and consideration of cardiac biomarkers. Management may include addressing underlying risk factors, prescribing physical activity and healthy dietary habits, and referral to a cardiologist.
Updated: 02/06/2022
- What are the heart risks associated with my cancer therapy?
- I have a family history of heart disease, is there anything I can do to protect my heart during or after treatment?
- Is heart monitoring needed during or after my cancer treatment?
- Should I be followed by a cardiologist?
The following studies look at the management of side effects:
Multiple cancers
- NCT02296450: Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments. This large study examines how skin conditions that are related to different kinds of cancer or cancer treatments affect a patient's overall well-being.
- NCT05056077: Tools to be Fit. This quality-of-life study examines the best tools for helping cancer survivors improve their diet, and exercise for people with bladder, breast, colon, endometrial, kidney (renal cell carcinoma), ovarian, or rectal cancer.
- NCT03996265: Bupropion in Reducing Cancer Related Fatigue in Cancer Survivors. This study tests how well the drug bupropion (Wellbutrin) reduces cancer-related fatigue for survivors.
Breast cancer
- NCT04586530: Telehealth and Memory Study (TAMS). This trial seeks to confirm the effectiveness of Memory and Attention Adaptation Training (TAMS), a cognitive-behavioral therapy as a treatment for chemotherapy-related dysfunction among breast cancer survivors.
- NCT02290834: Chemotherapy-induced cognitive and brain changes in older adults with breast cancer. This study investigates cognitive abilities and brain images before and after chemotherapy to identify people at risk for cognitive side effects and to better understand the effects of treatment on brain structure and function.
- NCT03879629: TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol (TACTIC). Breast cancer patients receiving Herceptin or other HER2-directed therapy are at risk of heart damage. This study looks at whether beta-blocker drugs could help prevent this from happening.
Colorectal cancer
- NCT05239338: Preserving Fertility After Colorectal Cancer Study (PREFACE). This study investigates the reproductive health and clinical outcomes among individuals ages 18 to 49 who are diagnosed with colorectal cancer.
- NCT06420726: Resistance Exercise and Creatine in Colorectal Cancer. This study assesses the feasibility of combining creatine supplementation with resistance training versus resistance training alone in colorectal cancer survivors.
Ovarian cancer
- NCT05047926: Prehabilitation for Advanced Ovarian Cancer Patients. This study tests whether structured activity for women undergoing chemotherapy improves their physical state before surgery and thus improves outcomes.
Prostate cancer
- NCT03971591: Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors (MMF). This study looks at Men Moving Forward (MMF), a community-based lifestyle intervention that supports adherence to nutrition and physical activity guidelines to promote improved body composition and lessen the side effects of treatment.
- NCT05155501: Pelvic Fascia spARing Radical Prostatectomy TrIAL (PARTIAL). This clinical trial studies whether pelvic fascia-sparing radical prostatectomy has similar cancer control and sexual function outcomes and significantly better urinary function, less penile deformity and inguinal hernia risks as compared to radical prostatectomy.
Updated: 03/11/2025
Who covered this study?
Fox News
Doctors warn of increased heart risks after treatment for breast cancer
This article rates 4.5 out of
5 stars
Forbes
Reasons not to freak out about risk of heart disease after breast cancer
This article rates 3.5 out of
5 stars
CBS News
Breast cancer treatments may increase heart risk, doctors warn
This article rates 3.0 out of
5 stars